Leveraging Human Primary Cell In Vitro Assays to Advance Immune-Targeted Cancer Therapeutics

The field of immuno-oncology has undergone profound changes in the last decade with thousands of new treatments now under development in the global drug discovery pipeline. With the rise of new therapeutics comes a need for robust in vitro assays that are able to accurately characterize the mechanisms of action and effector functions of new immunotherapies.

Dr. Gavin Meehan, senior study manager at Antibody Analytics, will discuss the different in vitro assays currently available for immuno-oncology drug discovery, and will provide an overview of the new types of assays in development.

Key learning objectives

• Learn about the various cell-type-specific assays available for characterizing different immunotherapies
• Discover how inducible cell lines can help better understand the binding capabilities of various therapeutics
• Explore how the transition towards more complex systems such as tissue organoids can provide more robust characterization data

Who should attend?

Researchers from both academia and industry who are interested in immunology and immuno-oncology

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.